CpG island methylation profile of estrogen receptor alpha in iranian females with triple negative or non-triple negative breast cancer: New marker of poor prognosis

Asian Pacific Journal of Cancer Prevention

Volumn 13, Issue 2, 2012, Pages 451-457

  Ramezani, Fatemeh ^a   Salami, Siamak ^b   Omrani, Mir Davood ^b   Maleki, Davood ^a  

^a URMIA UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b SHAHID BEHESHTI UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Breast cancer; CpG islands methylation; Estrogen receptor alpha; Triple negative phenotype

Indexed keywords

DNA; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR ALPHA, HUMAN; PROGESTERONE RECEPTOR; TUMOR MARKER;

ADULT; AGED; ARTICLE; BREAST TUMOR; CANCER GRADING; CANCER INVASION; COMPARATIVE STUDY; CPG ISLAND; DNA METHYLATION; ENZYME IMMUNOASSAY; FEMALE; GENE EXPRESSION REGULATION; GENE SILENCING; GENETICS; HUMAN; IRAN; MENOPAUSE; METABOLISM; MIDDLE AGED; PAGET NIPPLE DISEASE; PATHOLOGY; POLYMERASE CHAIN REACTION; PROGNOSIS; PROMOTER REGION; RETROSPECTIVE STUDY;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CPG ISLANDS; DNA METHYLATION; DNA, NEOPLASM; ESTROGEN RECEPTOR ALPHA; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE SILENCING; HUMANS; IMMUNOENZYME TECHNIQUES; IRAN; MENOPAUSE; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM INVASIVENESS; POLYMERASE CHAIN REACTION; PROGNOSIS; PROMOTER REGIONS, GENETIC; RECEPTOR, ERBB-2; RECEPTORS, PROGESTERONE; RETROSPECTIVE STUDIES; TUMOR MARKERS, BIOLOGICAL;

EID: 84866462479     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: 10.7314/APJCP.2012.13.2.451     Document Type: Article

References (37)

1. Ascenzi P, Bocedi A, Marino M (2006). Structure-function relationship of estrogen receptor alpha and beta: impact on human health. Mol Aspects Med, 27, 299-402.
2. Bae YK, Brown A, Garrett E, et al (2004). Hypermethylation in histologically distinct classes of breast cancer. Clin Cancer Res, 10, 5998-6005.
3. Buyru N, Altinisik J, Ozdemir F, et al (2009). Methylation profiles in breast cancer. Cancer Invest, 27, 307-12.
4. Conte P, Guarneri V (2009). Triple-negative breast cancer: current management and future options. Eur J Cancer, 7, 14-8.
5. Giacinti L, Claudio PP, Lopez M, et al (2006). Epigenetic information and estrogen receptor alpha expression in breast cancer. Oncologist, 11, 1-8.
6. Hanstein B, Djahansouzi S, Dall P, et al (2004). Insights into the molecular biology of the estrogen receptor define novel therapeutic targets for breast cancer. Eur J Endocrinol, 150, 243-55.
7. Harirchi I, Ebrahimi M, Zamani N, et al (2000). Breast cancer in Iran: a review of 903 case records. Public Health, 114, 143-5.
8. Harris L, Fritsche H, Mennel R, et al (2007). American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol, 25, 5287-312.
9. Herman JG, Graff JR, Myohanen S, et al (1996). Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci USA, 93, 9821-6.
10. Kolahdoozan S, Sadjadi A, Radmard AR, et al (2010). Five common cancers in Iran. Arch Iranian Med, 13, 143-6.
11. Kos M, Reid G, Denger S, et al (2001). Minireview: genomic organization of the human ERalpha gene promoter region. Molec Endocrinol, 15, 2057-63.
12. Lapidus RG, Nass SJ, Butash KA, et al (1998). Mapping of ER gene CpG island methylation-specific polymerase chain reaction. Cancer Res, 58, 2515-9.
13. Le Romancer M, Treilleux I, Bouchekioua-Bouzaghou K, et al. (2010). Methylation, a key step for nongenomic estrogen signaling in breast tumors. Steroids, 75, 560-4.
14. Lee JS, Fackler MJ, Teo WW, et al (2008). Quantitative promoter hypermethylation profiles of ductal carcinoma in situ in North American and Korean women: Potential applications for diagnosis. Cancer Biol Ther, 7, 1398-406.
15. Liu C, Zhang H, Shuang C, et al (2009). Alternations of ER, PR, HER-2/neu, and P53 protein expression in ductal breast carcinomas and clinical implications. Med Oncol, 27, 747-52
16. Macaluso M, Cinti C, Russo G, et al.(2003). pRb2/p130-E2F4/5-HDAC1-SUV39H1-p300 and pRb2/p130-E2F4/5-HDAC1-SUV39H1-DNMT1 multimolecular complexes mediate the transcription of estrogen receptor-alpha in breast cancer. Oncogene, 22, 3511-7.
17. Mehrotra J, Vali M, McVeigh M, et al (2004). Very high frequency of hypermethylated genes in breast cancer metastasis to the bone, brain, and lung. Clin Cancer Res, 10, 3104-9.
18. Mirza S, Sharma G, Prasad CP, et al (2007). Promoter hypermethylation of TMS1, BRCA1, ERalpha and PRB in serum and tumor DNA of invasive ductal breast carcinoma patients. Life Sci, 81, 280-7.
19. Mohagheghi MA, Mosavi-Jarrahi A, Malekzadeh R, et al (2009). Cancer incidence in Tehran metropolis: the first report from the Tehran Population-based Cancer Registry, 1998-2001. Arch Iranian Med, 12, 15-23.
20. Mousavi SM, Mohaghegghi MA, Mousavi-Jerrahi A, et al (2006). Burden of breast cancer in Iran: a study of the Tehran population based cancer registry. Asian Pac J Cancer Prev, 7, 571-4.
21. Mousavi SM, Mohagheghi MA, Mousavi-Jerrahi A, et al (2008). Outcome of breast cancer in Iran: a study of Tehran Cancer Registry data. Asian Pac J Cancer Prev, 9, 275-8.
22. Mousavi SM, Montazeri A, Mohagheghi MA, et al (2007). Breast cancer in Iran: an epidemiological review. Breast J, 13, 383-91.
23. Parl FF (2003). Multiple mechanisms of estrogen receptor gene repression contribute to ER-negative breast cancer. Pharmacogenomics J, ?, 251-3.
24. Parrella P, Poeta ML, Gallo AP, et al (2004). Nonrandom distribution of aberrant promoter methylation of cancer-related genes in sporadic breast tumors. Clin Cancer Res, 10, 5349-54.
25. Pinzone JJ, Stevenson H, Strobl JS, et al (2004). Molecular and cellular determinants of estrogen receptor alpha expression. Mol Cell Biol, 24, 4605-12.
26. Rasti M, Entezam M, Monabati A (2009). Hypermethylation of E-cadherin and estrogen receptor gene promoter and its association with clinicopathological features of breast cancer in Iranian patients. Iran J Medical Sci, 34, 186-92.
27. Riggins RB, Schrecengost RS, Guerrero MS, et al (2007). Pathways to tamoxifen resistance. Cancer Letters, 256, 1-24.
28. Sadjadi A, Nouraie M, Mohagheghi MA, et al (2005). Cancer occurrence in Iran in 2002, an international perspective. Asian Pac J Cancer Prev, 6, 359-63.
29. Salami S, Karami-Tehrani F (2003). Biochemical studies of apoptosis induced by tamoxifen in estrogen receptor positive and negative breast cancer cell lines. Clin Biochem, 36, 247-53.
30. Salami S, Ramezani F, Aghazadeh T, et al (2011). Impact of triple negative phenotype on prognosis and early onset of breast cancer in Iranian females. Asian Pac J Cancer Prev, 12, 719-24.
31. Seal MD, Chia SK (2010). What is the difference between triple-negative and basal breast cancers? Cancer J, 16, 12-6.
32. Szyf M, Pakneshan P, Rabbani SA (2004). DNA methylation and breast cancer. Biochem Pharmacol, 68, 1187-97.
33. Vahdaninia M, Montazeri A (2004). Breast cancer in Iran: a survival analysis. Asian Pac J Cancer Prev, 5, 223-5.
34. Viale G, Bottiglieri L (2009). Pathological definition of triple negative breast cancer. Eur J Cancer, 45, 5-10.
35. Wei M, Xu J, Dignam J, et al (2008). Estrogen receptor alpha, BRCA1, and FANCF promoter methylation occur in distinct subsets of sporadic breast cancers. Breast Cancer Res Treat, 111, 113-20.
36. Yoshida T, Eguchi H, Nakachi K, et al (2000). Distinct mechanisms of loss of estrogen receptor alpha gene expression in human breast cancer: methylation of the gene and alteration of trans-acting factors. Carcinogenesis, 21, 2193-201.
37. Zhao L, Wang L, Jin F, et al (2008). Silencing of estrogen receptor alpha (ERalpha) gene by promoter hypermethylation is a frequent event in Chinese women with sporadic breast cancer. Breast Cancer Res Treat, 117, 253-9.